Cellular quality control process could be Huntington's disease drug target

February 13, 2017, Duke University Medical Center
Misfolded proteings in cells of people with Huntington's disease cause the death of neurons in brain and muscle cells in the body. Scientists have known that in people with Huntington's, chaperone proteins -- whose job it is to fold misfolded proteins 0 are at low levels, but it wasn't clear why. Credit: Alisa Weigandt for Duke Health

The loss of motor function and mental acuity associated with Huntington's disease might be treatable by restoring a cellular quality control process, which Duke Health researchers have identified as a key factor in the degenerative illness.

Huntington's disease is an inherited condition that results in the gradual erosion of , leading to impairments and death. It affects about one in 10,000 people in the United States and has no cure.

Like other neuro-degenerative diseases such as Alzheimer's and Parkinson's, Huntington's disease is caused when certain molecules fail to fold into the proper structural shape required for them to function properly. These misfolded proteins build up and become toxic to the nerve cells that control movement and thought.

In a study published online Feb. 13 in the journal Nature Communications, Duke Health researchers looked at what causes the failure of the cellular process that usually fixes or discards these misfolded proteins.

"Normally when proteins misfold, the cells have a mechanism to cope," said senior author Dennis Thiele, Ph.D., George Barth Geller Professor in the Department of Pharmacology and Cancer Biology. "These quality control mechanisms can prod the proteins back into their normal three-dimensional shape, or if the damage is too extensive, target them for removal in the cellular garbage disposal. In Huntington's disease, that's not happening."

Thiele and colleagues conducted experiments using yeast genetics, biochemistry, chemical biology screening, mouse models and stem cells from patients with Huntington's disease. They found a biochemical explanation for how the process breaks down in Huntington's disease.

They focused on specialized proteins called chaperones—helpmates that coax the into their correct conformations. Chaperone proteins are abnormally scarce in people with Huntington's disease, but the cause of that scarcity was not known until now.

The Duke-led team found that the master control for chaperone production, called HSF1, was being destroyed in Huntington's disease due to the presence of abnormally high levels of a chemical modifier called CK2. As a result, neurons die due to their inability to produce sufficient levels of the beneficial chaperones.

"We demonstrated that we could restore the abundance of the protein chaperones by chemically inhibiting CK2 in a cell model of Huntington's disease, or genetically lowering CK2 kinase levels in a Huntington's disease mouse model," Thiele said. "In both cases, we dramatically increased the number of healthy neurons and we prevented the muscle wasting that is commonly observed in Huntington's disease."

With more functioning neurons, he said, the hallmarks of Huntington's disease diminish. Thiele said there are potential investigational drugs that could delay or prevent the cellular processes that cause the neurodegeneration of Huntington's disease, and could also be tested in Alzheimer's and Parkinson's, along with other similar diseases.

But he said more pre-clinical studies are needed to explore those chemicals and to further illuminate the cellular events involved.

"We have identified a potential new target for a drug intervention in Huntington's disease," Thiele said, "but there are a lot of basic questions that still need to be answered."

Explore further: Potential therapeutic target for Huntington's disease

Related Stories

Potential therapeutic target for Huntington's disease

August 16, 2016
There is new hope in the fight against Huntington's disease. Scientists at the Gladstone Institutes discovered that changing a specific part of the huntingtin protein prevented the loss of critical brain cells and protected ...

Huntington's disease linked to dysfunction of brain structure

December 21, 2016
Northwestern Medicine scientists identified a link between Huntington's disease and dysfunction of the subthalamic nucleus, a component of the basal ganglia, a group of brain structures critical for movement and impulse control.

Scientists develop therapeutic protein, protect nerve cells from Huntington's Disease

September 13, 2016
A new scientific study reveals one way to stop proteins from triggering an energy failure inside nerve cells during Huntington's disease. Huntington's disease is an inherited genetic disorder caused by mutations in the gene ...

Study indicates that the hippocampus mediates cognitive decline in Huntington's disease

September 2, 2014
Huntington's disease is a neurodegenerative disorder that results in involuntary spastic movement and loss control of voluntary motor function. Patients also exhibit a decline in cognitive ability. The defects in learning ...

Recommended for you

Convergence of synaptic signals is mediated by a protein critical for learning and memory

July 16, 2018
Inside the brain, is a complex symphony of perfectly coordinated signaling. Hundreds of different molecules amplify, modify and carry information from tiny synaptic compartments all the way through the entire length of a ...

'Concussion pill' shows promise in pre-clinical pilot study

July 16, 2018
In 2016, funded by a $16 million grant from Scythian, the multidisciplinary Miller School team embarked on a five-year study to examine the effects of combining CBD (a cannabinoid derivative of hemp) with an NMDA antagonist ...

Synapse-specific plasticity governs the identity of overlapping memory traces

July 16, 2018
Memories are formed through long-term changes in synaptic efficacy, a process known as synaptic plasticity, and are stored in the brain in specific neuronal ensembles called engram cells, which are activated during corresponding ...

Fetal gene therapy prevents fatal neurodegenerative disease

July 16, 2018
A fatal neurodegenerative condition known as Gaucher disease can be prevented in mice following fetal gene therapy, finds a new study led by UCL, the KK Women's and Children's Hospital and National University Health System ...

Rehabilitating the mind could improve outcomes after spinal cord injury

July 16, 2018
A study led by Heriot-Watt University has explored how individuals with spinal cord injuries perceive the space around them. The findings suggest additions are needed to the rehabilitation programmes adopted post-injury to ...

Study suggests mice and rats, like humans, make poor choices based on 'sunk costs'

July 13, 2018
A team of researchers at the University of Minnesota has found that mice and rats, like humans, tend to make poor decisions based on "sunk costs." In their paper published in the journal Science, the group describes their ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.